Overweight as a Favorable Clinical Biomarker for Checkpoint Inhibitor Therapy Response in Recurrent Gynecologic Cancer Patients

Despite increasing clinical interest in adapting checkpoint inhibitor (CPI) therapies for patients with gynecologic malignancies, no accurate clinical biomarkers to predict therapy response and prognosis are currently available. Therefore, we aimed to assess the predictive and prognostic value of pr...

Descrizione completa

Dettagli Bibliografici

Autori principali:	Thomas Bartl, Arina Onoprienko, Gerda Hofstetter, Leonhard Müllauer, Nina Poetsch, Thorsten Fuereder, Paul Kofler, Stephan Polterauer, Christoph Grimm
Natura:	Artigo
Lingua:	Inglês
Pubblicazione:	MDPI AG 2021-11-01
Serie:	Biomolecules
Soggetti:	immunotherapy immune checkpoint inhibitor biomarker overweight RECIST
Accesso online:	https://www.mdpi.com/2218-273X/11/11/1700
Tags:	Aggiungi Tag Nessun Tag, puoi essere il primo ad aggiungerne!!